A randomized, double blinded, split-face study of efficacy and safety of topical 0.05% Oxymetazoline on post acne erythema
- Conditions
- Patients with mild to severe post acne erythema according to Clinician erythema assessment criteriaPost acne erythema, Oxymetazoline hydrochloride
- Registration Number
- TCTR20211207004
- Lead Sponsor
- /A
- Brief Summary
Our study demonstrated that the OxH 0.05% solution is well-tolerated, safe, and effective for reducing PAE without a rebound effect. We proposed that this over-the-counter drug for nasal congestion could be an alternative treatment for PAE.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 30
1. Subjects aged 18-45 years diagnosed by a dermatologist for mild to severe post acne erythema according to Clinician erythema assessment criteria.
2. Subjects who are informed in detail about the research study and express their interests in participation.
3. Subjects with redness scores from the VISIA differed by no more than 10% on both sides of the face.
1. Subjects with a history of rosacea or other active dermatitis on the treatment site. 2. Previously known allergic reaction to oxymetazoline 3. Subjects with a past medical history of hypertension, asthma, cardiovascular disease, cerebrovascular disease, vascular disease, close angle glaucoma, hypotension, or postural hypotension. 4. Female subjects who are currently in pregnancy or breastfeeding 5. Subjects who had previously treated post acne erythema with topical medications such as azelaic acid, or other facial procedures such as lasers, injections, or any chemical treatment within three months before study enrollment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of post acne erythema leision week 0, 2,4, 8, 12 PAE leision counts
- Secondary Outcome Measures
Name Time Method Erythema score week 0, 2,4, 8, 12 Visia image analysis for erythema score evaluation,Erythema score week 0, 2,4, 8, 12 Chroma meter CR-400,Erythema Score week 0, 2,4, 8, 12 Clinician erythema assessment scale,Adverse effect week 0, 2,4, 8, 12 number of events,Satisfaction score after treatment week 0, 2,4, 8, 12 Subject's assessment by visual analogue scales(VAS)